Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
Key Highlights
- ➤Nov. 6 call will update clinical and regulatory strategy for BASECAMP
- ➤BASECAMP Phase 2 studies boys ages 7, 8 or 9 with DMD
- ➤Forazapadin evaluated in BASECAMP and TRAILHEAD Phase 2 DMD trials
- ➤FSHD IND application for forazapadin has been cleared
Expert Statements
Frank Gleeson, Co-founder and Chief Executive Officer of Satellos Bioscience
“The article does not provide a direct quote from Frank Gleeson.”
Wildon Farwell, M.D., Chief Medical Officer of Satellos Bioscience
“The article does not provide a direct quote from Wildon Farwell, M.D.”
TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially life-improving medicines to treat degenerative muscle disorders, today announced that it will host a conference call and audio webcast at 8:00 a.m. ET on Friday, Nov. 6, 2026, to provide an update on the clinical and regulatory strategy for BASECAMP, the Company’s Phase 2 pediatric study in boys ages 7, 8 or 9 with Duchenne muscular dystrophy (DMD). The call will feature remarks from Satellos Co-founder and Chief Executive Officer Frank Gleeson and Chief Medical Officer Wildon Farwell, M.D.
A live webcast of the conference call and accompanying slides will be available on the Events and Presentations page of the Investors section of the Company’s website. A replay will be available following the presentation.
Get started
Create a free account to read the full story.